SSelectStock

JAGSNPHARMJagsonpal Pharmaceuticals Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.

232.89
0.04%
64Decent

Mkt Cap
₹1,539 Cr
P/E
34.7
P/B
6.0
Div Yield
1.03%
52W High
₹264.50
52W Low
₹155.00

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)1,539.30
P/E34.66
P/B5.97
PEG1.36
ROE %15.60
ROCE %17.10
Debt / Equity0.03
EPS6.72
Revenue Growth %8.80
Profit Growth %25.30
Dividend Yield %1.03
Promoter Holding %76.09
FII Holding %2.58
DII Holding %
Beta-0.35

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

None of the 16 pattern scanners currently detects a setup on JAGSNPHARM — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.

HOLDConviction 66%

The picture

  • Profit growth: 25.3% YoY
  • ROCE: 17.1%
  • Debt/Equity: 0.03
  • Price vs SMA50: above
  • Price vs SMA200: above
  • Golden cross setup: SMA50 above SMA200

Bull case

  • Profit growth: 25.3% YoY
  • ROCE: 17.1%
  • Debt/Equity: 0.03
  • Price vs SMA50: above

Bear case

  • MACD: bearish
  • Price vs EMA21: below
  • Volume trend: 0.2x baseline
  • Max drawdown (1y): 36%

Key risks

  • Elevated volatility / drawdown profile — size positions accordingly
  • MACD: bearish
  • Price vs EMA21: below

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹232.89
Stop Loss
₹222.38
risk 4.5%
Target 1 (1.5R)
₹248.65
+6.8%
Target 2 (3R)
₹264.41
+13.5%
Support (20d)
₹224.63
Resistance (52w)
₹264.50
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹10.51/share
ATR (volatility)
₹8.24
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹8.24). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental77
Technical57
Momentum74
Risk (safety)37

Peers — Pharma

CORONA 1.60%
87
GRANULES 1.12%
81
LAURUSLABS 1.23%
79
KPL 3.75%
79
DIVISLAB 1.23%
79
CAPLIPOINT 1.45%
78